Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT01030952
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, 600 Xuanshan Road, Shanghai, China
🇨🇳Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, China
🇨🇳Shanghai Tongji Hospital, 389 Xinchun Road, Shanghai, China
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
- Conditions
- CancerNeoplasmsTumors
- Interventions
- Drug: TKI258 (dovitinib)
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01030055
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Duke University Medical Center Cancer Dept, Durham, North Carolina, United States
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
- Conditions
- Acute Gout
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT01029652
- Locations
- 🇸🇪
Novartis Investigative site, Stockholm, Sweden
🇺🇦Novartis Investigative Site, Zaporizhzhya, Ukraine
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT01028222
- Locations
- 🇺🇸
Baylor Health Care System/Sammons Cancer Center Baylor 2, Dallas, Texas, United States
🇺🇸University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Case Western Reserve Case Western, Cleveland, Ohio, United States
Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients
- Conditions
- Kidney Transplant
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 613
- Registration Number
- NCT01025817
- Locations
- 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 767
- Registration Number
- NCT01023308
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT01022996
- Locations
- 🇺🇸
Duke University Medical Center Duke University Medical Ctr, Durham, North Carolina, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4, Madison, Wisconsin, United States
🇺🇸Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01022970
- Locations
- 🇺🇸
Stanford Medical Center and Lucile Packard Children's Hospital, Stanford, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Minnesota, Minnesota, United States
A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: VAK694; Alutard Avanz SQDrug: VAK694 placebo infusion; Alutard Avanz SQDrug: VAK694 placebo infusion; Saline
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT01018693
- Locations
- 🇬🇧
Novartis Investigator Site, London, United Kingdom
Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT01019980
- Locations
- 🇻🇪
Ciudad Hospitalaria Enrique Tejera, Valencia, Estado Carabobo, Venezuela
🇻🇪Hospital de niños "J. M. de los Rios", Distrito Metropolitano, Caracas, Venezuela